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according to the location of the drugstore and in accordance with the area of capacity 
in the workers of ANVISA. RESULTS: There were interviewed 105 consumers in 
drugstores and 140 workers of ANVISA. When asked about the existence of market 
regulation of drugs, 51.43% and 87.14% of drug users and employees of ANVISA, 
respectively, said there is regulation of these products. About the PMC, the knowledge 
was 20.00% of respondents in pharmacies and 57.86% of the employees of ANVISA. 
Despite of the relative knowledge of PMC, only 01 of the respondents knew where 
consumers search the PMC, and the employees of ANVISA, 29 knew the sources of 
research. Although the poor knowledge on the regulation of prices, 84.76% of con-
sumers interviewed considered this activity exerted by the government as important. 
CONCLUSIONS: Although the population consider important that the prices of 
medicines are regulated by the government, the knowledge of the regulation is small, 
even on the tools of consumer protection.
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OBJECTIVES: This study was investigating of costs and consequences of two manual 
and computerized systems for management of information during 2008–2009 for 
inspection of pharmaceutical industries in Iranian Drug Regulatory Affairs. 
METHODS: To compute costs of processes following items had been considered: Cost 
of ﬁ lling and archiving, data collecting (person-hour), reporting (person-hour), trans-
port, software, hardware (main server computer, pocket computer), stationeries. To 
evaluate the efﬁ cacy following outputs and outcomes was considered: Time of infor-
mation recovering, ability of ranking, preventing of data missing, capacity building 
and tracking and monitoring. RESULTS: The cost of running the new system is 35,000 
US Dollars. Cost of education in new method and conventional are 5000 and 1000 
US Dollars respectively. Cost of inspection in computerized management of informa-
tion system (MIS) is decreased to 250 US Dollars from 600 US Dollars for each 
inspection process. Alongside capacity of system is increased by arming to fast process-
ing method, time of information recovering diminished to 1 working day instead of 
3 days, preventing of data missing from 80% to 95% in new one, tracking and moni-
toring took 7 working days to applied, but new MIS changed that to 1 working day. 
Ranking of pharmaceutical industries is now available for Iranian Drug Regulatory 
Affairs after establishment of new inspection system by computer-based MIS. CON-
CLUSIONS: It seems that beside overhead cost of new computerized system that is 
more than conventional method; considering capacity building; due to decreasing the 
cost of inspection and increasing of outputs and outcomes indicators, the new system 
is more efﬁ cient.
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OBJECTIVES: Patients, health service providers, payers and the society also gain from 
intensive clinical trial participation, however the majority of beneﬁ ts are intangible. 
According to a recent survey Hungary generates 0.15% of the GDP from clinical trials 
and related activities, therefore the economic importance of this area is acknowledged 
by the Hungarian government. The clinical trial activity is traditionally strong in the 
country, however the growth rate of clinical trials is lower than in other Central-
Eastern European countries. Our objective was to explore how Hungary can improve 
its competitiveness in attracting clinical trials. METHODS: We conducted a literature 
review, searched for publicly available documents and interviewed key stakeholders 
in Hungary to explore potential ﬁ elds for intervention. RESULTS: We identiﬁ ed seven 
key target areas for intervention to improve the competitiveness of Hungary in clinical 
trials: the simpliﬁ cation of legal framework for clinical trial related activities, develop-
ment of infrastructure at main potential sites, organizational development with special 
focus on SMOs, the simpliﬁ cation of rules and processes for ﬁ nancing clinical trials, 
investment into developing databases to support the set-up of clinical trials, and ﬁ nally 
the marketing promotion of Hungary and its sites to sponsors of clinical trials. CON-
CLUSIONS: The area of international clinical trials is a very competitive market. 
Hungary can strengthen its market position, if legislators, competent authorities and 
management teams of investigational sites—by acknowledging the professional and 
ﬁ nancial beneﬁ ts of these studies—support the successful implementation of clinical 
trials in coordinated actions.
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OBJECTIVES: To analyze the effects of liberalization of regulations, concerning 
establishment of pharmacies and pharmacy points in Poland after 1989. METHODS: 
The data on the number of pharmacies and pharmacy points, used for the analysis were 
collected by mail survey completed by all regional pharmaceutical supervision authori-
ties. Population data were sourced from the statistical yearbook of Poland. RESULTS: 
During economic transition Poland was one of few European Union countries, where 
the number of pharmacies was not regulated within a given area. Therefore, their 
numbers increased rapidly, reaching 12.153 private pharmacies and 1.397 private 
pharmacy points in 2009. This means that in 2009 one pharmacy served 3.127 people. 
Before privatization process started in 1989, all retail pharmacies were managed by a 
state-owned enterprise “Cefarm”. Since then, the regulations have changed and the 
number of pharmacies started to grow. The main reasons of this trend was a regulation 
stipulating that permission to establish a pharmacy can be granted to any private or 
legal person, disregarding professional education of that person. Pharmacy owner was 
only required to employ a qualiﬁ ed pharmacist, responsible for managing the phar-
macy. Another major institutional change was introduced by the Pharmaceutical Law, 
voted October 10, 1991, which authorized establishment of pharmacy points. In spite 
of the general trend, in some poor provinces of Poland the number of pharmacies 
decreased. June 1, 2010, European Court of Justice ruled that the right to own and 
operate a pharmacy may be reserved exclusively for pharmacists and that demographic 
or geographic criteria may be used in the process of issuing permits to operate pharma-
cies. CONCLUSIONS: Currently, the Polish Ministry of Health has to propose 
amendments to the Pharmaceutical Law, implementing the above mentioned 
criteria.
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OBJECTIVES: To investigate changes realized in the Czech pricing and reimbursement 
system since January 2008 and to describe the current development of this system. 
METHODS: We described the legal framework deﬁ ning the Czech system (Act No. 
48/1997 Coll. as amended by the Act No. 261/2007 Coll. on Public Health Insurance) 
as well as evaluation of the current system from the literature and reports provided 
by the State Institute for Drug Control (SUKL). RESULTS: In order to increase trans-
parency according to EU Transparency Directive and to set fairly-deﬁ ned deadlines 
the competencies for the pricing and reimbursement system were merged from Min-
istries of Finances and Ministry of Health (MoH) under one responsible institution—
SUKL. The pricing rules were fully changed—the maximum price is set based as the 
mean value of all available ex-factory prices in the reference countries (Estonia, France, 
Italy, Lithuania, Hungary, Portugal, Greece and Spain). The reference reimbursement 
system contains 251 reference groups of therapeutically interchangeable products with 
similar clinical efﬁ cacy and safety (should be updated annually by MoH). Medicinal 
products included in one reference group have the main common therapeutic indica-
tion in the same reimbursement level which is calculated on the basis of retail prices 
in all EU countries. The cheapest price for equipotent dose is chosen and re-counted 
according to local pharmacy and wholesaler margins and value added taxes. In compli-
ance with new legislation the pharmacoeconomic criteria (cost-effectiveness evaluation 
and budget impact analysis) should be taken into account. There is possibility of extra 
bonus of basic reimbursement for better efﬁ cacy, safety, dosing schedule, compliance, 
etc. CONCLUSIONS: The system has gone through dramatic changes in last two years 
and some aspects are still facing challenges. Although the new system should reassessed 
all medicines covered in the country till 2008, currently there are only 20% revised 
(April 2010). 
HEALTH CARE USE & POLICY STUDIES – Risk-Sharing/Performance-Based 
Scheme/Agreements
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OBJECTIVES: Whilst patient access schemes (PAS) are not a new concept, they are 
clearly receiving increasing attention. The ﬁ rst notable PAS, devised to improve access 
to beta interferons for multiple sclerosis, was an outcomes-based scheme designed to 
overcome uncertainty in long-term clinical and cost-effectiveness. It is the nature of 
the uncertainty that drives the design of PAS, but is there a trend towards which 
schemes are more popular? We analyzed the design of published PAS employed in the 
UK in order to determine if outcomes-based or ﬁ nancial-based schemes predominate. 
METHODS: Published PAS were identiﬁ ed from health technology assessment web-
sites (e.g. the National Institute for Health and Clinical Excellence and Scottish Medi-
cines Consortium), literature searching of ISPOR conference abstracts, and searching 
of ‘patient access scheme’ or ‘risk-sharing scheme,’ using internet search engines. PAS 
identiﬁ ed were categorised as ﬁ nancial-based (price- or volume-based agreements) or 
outcomes-based schemes. Desk research was the performed to identify the preference 
for each type of scheme, in terms of uptake by UK Primary Care Trusts. RESULTS: 
Seventeen published PAS were identiﬁ ed from the literature search, from 2002 until 
2010. Categorization of PAS as ﬁ nancial-based versus outcomes-based showed that 
schemes were balanced, but favoured ﬁ nancial-based schemes (59% versus 41%, 
respectively). The uptake of ﬁ nancial-based schemes was found to be higher than 
outcomes-based schemes due to administrative burden posed by schemes which rely 
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on the measurement and reporting of clinical outcomes. CONCLUSIONS: PAS were 
pioneered by the beta interferon outcomes-based scheme for multiple sclerosis, 2002. 
Since then, published UK-based schemes favour price or volume-based schemes, a 
trend illustrated by two of the three newest schemes published in 2010. The simplicity 
of ﬁ nancial-based agreements, combined with poor health care system uptake of 
outcomes-based schemes and the demand for value-based pricing, suggests that this 
trend is set to continue.
PHP126
PATIENT ACCESS SCHEMES (PAS) IN THE UK COMING OF AGE: WHAT 
IMPACT WILL THEY HAVE ON OTHER EU COUNTRIES LIKE ITALY?
Kirpekar S, Mallinson M, White R, Gannedahl A
Double Helix Consulting Group, London, UK
OBJECTIVES: Although patient access schemes (PAS) have historically been imple-
mented for high-cost oncology drugs, recent schemes for chronic diseases like rheu-
matoid arthritis (RA) have been seen in the UK. This study tries to understand how 
the shift in PAS from being accepted by payers only for short-term oncology drugs to 
those for chronic diseases like RA in the UK will inﬂ uence the situation in Italy, where 
PAS are known to be widespread. METHODS: This study used qualitative telephone 
interviews to analyze trends in the UK (n = 7) and Italy (n = 7). Interviews were 
conducted in tertiary hospitals as well as local, regional and national level reimburse-
ment authorities involving ﬁ nancial and clinical stakeholders, and key individuals in 
the implementation of the scheme. Importance of a number of variables affecting new 
PAS was ranked. RESULTS: Budget-holders in both markets were seen to be sceptical 
about the impact on long-term budgets due to the move towards PAS for chronic 
conditions. Of the 14 stakeholders interviewed, 9 said that such schemes in chronic 
conditions might help companies access markets with lesser clinical evidence on the 
basis of the class-effect of the drugs and the risk-sharing nature of the schemes. Moni-
toring of the outcomes on implementation was thought to be crucial. CONCLU-
SIONS: In Italy, increase in PAS for chronic diseases will help drug companies bring 
drugs to the market earlier. On the other hand, the payers will see this as an increased 
burden on their budgets as it will mean funding longer term treatment. Also, due to 
recent issues with monitoring of outcomes in PAS in the UK, their future needs re-
consideration. This move of PAS towards chronic conditions is expected to increase 
the impact that post-marketing monitoring will have on market access for expensive 
‘me-too’ drugs in the EU.
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OBJECTIVES: To explore major stakeholders’ incentives and disincentives to adopt 
a ﬁ nancial risk-sharing mechanism regarding budget-impact estimates of adopting new 
technologies in the Israeli National List of Health Services (NLHS). According to the 
proposed scheme, HMOs will be partially compensated by the pharmaceutical and 
medical device industry if actual use of a technology is substantially higher than what 
was projected and allocated. On the other hand, HMOs will partially refund the 
government for budgets allocated to speciﬁ c technologies that were not fully used. 
These unused budgets will be used for adopting other technologies in subsequent years. 
METHODS: Using a semi-structured protocol, we interviewed major stakeholders 
involved in the process of updating the NLHS (N = 31). Interviewees included govern-
ment ofﬁ cials, senior managers in the country’s four HMOs, pharmaceutical industry 
executives, and health economists. We inquired into the interviewee’s view towards 
our proposed risk-sharing mechanism, and their opinion on the other stakeholders’ 
incentives to accept or object the proposed scheme. RESULTS: Our interviews revealed 
a wide range of incentives, disincentives, and barriers for adopting the risk-sharing 
mechanism. There was no consensus on what would be the different stakeholders’ 
incentives and disincentives for adopting the proposed mechanism, even within the 
various stakeholders groups themselves. Most interviewees from the HMOs and the 
pharmaceutical industry supported the proposed risk-sharing agreement. Among gov-
ernment ofﬁ cials, the Ministry of Finance decision-makers tended to object to the 
proposed mechanism, while Ministry of Health executives usually supported the 
scheme, but believed that the pharmaceutical industry will not support this risk-
sharing agreement. CONCLUSIONS: Since the success of implementing a risk-sharing 
mechanism depends mainly on its perception as a win-win situation for all stakehold-
ers, we recommend that decision-makers consider the different incentives and disincen-
tives exposed in our interviews, when implementing such a mechanism. 
HEALTH CARE USE & POLICY STUDIES – Beyond Drug Interventions
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OBJECTIVES: Growing attention is currently given to preventive health care. Preven-
tion can decline the appearance of several diseases and as a consequence lead to a 
decrease of health care expenses. The aim of this study was to evaluate if municipalities 
in Belgium currently are using intervention strategies for optimizing the health behav-
ior of citizens. Special attention was given to what extent certain high-risk groups are 
reached. METHODS: The design consisted of a retrospective observational design. 
The general services or—if existing—the sports services of 570 Belgian cities (308 in 
the Flanders and 262 in the Walloon region) were invited by e-mail to participate in 
the study. After the ﬁ rst mailing, another two mailings were performed. The data were 
collected using an online questionnaire with closed questions. PASW Statistics 18 was 
used for statistical analysis. RESULTS: The response rate in the Flemish region and 
Walloon region was respectively 57.47% and 16.41%. In Flanders, 94.9% of respon-
dents reported that they organize health promotion initiatives, while in Wallonia this 
percentage was 65.1%. Most common organized initiatives in the Flanders region 
were sport (74.4%) and social welfare (46.4%) initiatives. In Wallonia most common 
initiatives were prevention of disease/vaccination (45.3%) and sport (44%). Both in 
Flanders and Wallonia, initiatives concerning mental health were little organized. In 
general, the initiatives aimed at certain high-risk groups such as persons with mental 
health problems, older and disabled persons were scarce. On the level of municipal 
policy lack of appropriate ﬁ nancing was reported as the most common barrier for not 
organizing preventive strategies. CONCLUSIONS: On the level of municipal policy 
reinforcement of the value of preventive strategies concerning health promotion with 
appropriate ﬁ nancing is required. When organizing preventive initiatives, special atten-
tion to reach certain high-risk groups will be needed.
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OBJECTIVES: The issue of the introduction of co-payments is a great policy challenge 
in most of the Central-Eastern European countries. This is also the case in Hungary, 
where visit fee was introduced for health care services in 2007, and abolished one year 
later as a result of a referendum. The aim of our study is to identify different types 
of attitudes towards patient payments, and answer why visit fee was so unpopular 
among Hungarian population. METHODS: 8 focus-group discussions with health 
care consumers and physicians and 7 in-depth interviews with policy makers were 
conducted in Hungary during the summer 2009 on the attitude of patient payments 
in health care. RESULTS: Based on the transcripts and questionnaires ﬁ lled in by all 
respondents during the focus group discussions and interviews three different groups of 
attitude were identiﬁ ed. The group of “Supporters” support the introduction of patient 
payments with the aim of controlling the unnecessary use of services. The group of 
“Undecided” concern patient payments as an opportunity to provide additional resource 
for health care system by paying for “extra-better-quality services”. “Sceptics” strongly 
refuse the idea of patient payments mainly referring to ethical issues. Consumers mainly 
belong to the group of “Undecided”, while one part of the physicians belongs to “Sup-
porters”, the other part to “Sceptics”. Policy makers are all belong to the group of 
“Supporters”. CONCLUSIONS: Before the implementation of patient payments, 
mapping of population’s attitude is inevitable. In Hungary the failure of the introduc-
tion of visit fee can be explained by different expectations of health care consumers. 
They are not against to pay for health care services, but expecting better quality of 
provided services in return.
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OBJECTIVES: In the current economic climate health authorities are ﬁ nding ways to 
control spending. a popular measure is the introduction of cost containment strategies 
for pharmaceuticals to lessen the burden of cost of drugs. The objective of this research 
was to analyze the importance of different cost containment measures that payers use 
in selected markets. The research extends to analyze the gaps between the policies on 
paper and the extent these are interpreted and executed in practice. METHODS: 
Interviews were conducted with payers at the national, regional and local level in 
selected European and non-European markets. RESULTS: All countries utilise differ-
ent measures to control spending on pharmaceuticals. The measures that are used by 
markets include: internal therapeutic referencing, international price referencing, 
generic substitution, risk-sharing agreements, budget caps, proﬁ t caps, index pricing, 
price cuts, rebates and price volume agreements. The critical ﬁ nding from the research 
was that although combinations of measures are included in the national and regional 
policies, in reality their interpretation and execution varies substantially. For example, 
Spain uses internal referencing and price referencing at the national level, regions apply 
price discounts and rebates. Similarly, in the The Netherlands a preferred drug policy 
is introduced, which means that health insurers can now choose a preferred drug for 
reimbursement, which is usually the cheapest option of the reference basket. If the 
patient does not want this product, they have to pay the full price of the other product. 
Another European country which has become the recent focus is Germany; where 
price regulation will become dominant in the near future. There are uncertainties on 
achievable prices of drugs, one reason being there is lack of sophisticated systems in 
place that can monitor these measures. CONCLUSIONS: There are currently many 
developments in the area of cost containment of pharmaceuticals which will have a 
profound effect on the pharmaceutical industry.
